Mediclinic International (LON:MDC) has been assigned an average recommendation of “Hold” from the ten ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is GBX 690.22 ($9.88).
A number of brokerages recently issued reports on MDC. Barclays began coverage on shares of Mediclinic International in a research report on Friday. They set an “overweight” rating and a GBX 751 ($10.75) price target for the company. UBS cut shares of Mediclinic International to a “neutral” rating and lifted their price target for the company from GBX 600 ($8.59) to GBX 650 ($9.31) in a research report on Tuesday, January 30th.
Shares of MDC traded down GBX 0.40 ($0.01) during trading hours on Wednesday, reaching GBX 591.20 ($8.47). 1,020,785 shares of the company traded hands, compared to its average volume of 1,610,000. Mediclinic International has a 12 month low of GBX 495.40 ($7.09) and a 12 month high of GBX 890.18 ($12.75).
Mediclinic International Company Profile
Mediclinic International plc is an international private healthcare provider. The Company’s segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services. It has interest in Spire Healthcare, a United Kingdom-based private healthcare company.
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.